Geriatric Nursing
Volume 28, Issue 3 , Pages 171-181 , May 2007

Identification, Optimal Management, and Infection Control Measures for Clostridium difficile–Associated Disease in Long-Term Care

References 

  1. Simor AE, Bradley SF, Strausbaugh LJ, et al. The SHEA Long-Term Care Committee Clostridium difficile in long-term care facilities for the elderly (SHEA Position Paper). Infect Control Hosp Epidemiol. 2002;23:696–703
  2. Poutanen SM, Simor AE. Clostridium difficile–associated diarrhea in adults. Can Med Assoc J. 2004;171:51–58
  3. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334–339
  4. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile–associated diarrhea: a review. Arch Intern Med. 2001;161:525–533
  5. Bender BS, Bennett R, Laughon BE, et al. Is Clostridium difficile endemic in chronic-care facilities?. Lancet. 1986;2:11–13
  6. Thomas DR, Bennett RG, Laughon BE, et al. Post-antibiotic colonization with Clostridium difficile in nursing home patients. J Am Geriatr Soc. 1990;38:415–420
  7. Simor AE, Yake SL, Tsimidis K. Infection due to Clostridium difficile among elderly residents of a long-term-care facility. Clin Infect Dis. 1993;17:672–678
  8. Johnson S, Clabots CR, Linn FV, et al. Nosocomial Clostridium difficile colonisation and disease. Lancet. 1990;336:97–100
  9. Shim JK, Johnson S, Samore MH, et al. Primary symptomless colonization by Clostridium difficile and decreased risk of subsequent diarrhea. Lancet. 1998;351:633–636
  10. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial. Ann Intern Med. 1992;117:297–302
  11. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204–210
  12. Centers for Disease Control and Prevention. Fact Sheet. 2004;August (updated July 22, 2005)
  13. Johnson SJ, Gerding DN. Clostridium difficile. In:  Yu V editors. Antimicrobial therapy and vaccines. 2nd ed. New York: Apple Trees Productions; 2002;p. 214
  14. Warny M, Pépin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–1084
  15. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390–397
  16. Sunenshine RH, McDonald LC. Clostridium difficile–associated disease: new challenges from an established pathogen. Cleveland Clin J Med. 2006;73:187–197
  17. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40:1–15
  18. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile–associated diarrhea and colitis in adults: a perspective case-controlled epidemiologic study. Arch Intern Med. 1986;146:95–100
  19. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. Ann Intern Med. 1974;81:429–433
  20. Pear S, Williamson T, Bettin K, et al. Decrease in nosocomial Clostridium difficile–associated diarrhea by restricting clindamycin use. Ann Intern Med. 1994;120:272–277
  21. Linder JA, Huang ES, Steinman MA, et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118:259–268
  22. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004;38:640–645
  23. Loo VG, Poirier L, Miller A, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–2449
  24. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–1260
  25. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and Clostridium difficile–associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990;162:678–684
  26. Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile–associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol. 1991;12:34–48
  27. Kim KH, Fekety R, Blatts DH, et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis. 1981;143:42–50
  28. Pierce PF, Wilson R, Silva J, et al. Antibiotic-associated pseudomembraneous colitis: an epidemiologic investigation of a cluster of cases. J Infect Dis. 1982;145:269–274
  29. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric-acid suppressive agents and the risk of community-acquired Clostridium difficile–associated disease. JAMA. 2005;294:2989–2995
  30. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–1260
  31. Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med. 2006;166:2518–2524
  32. Lowe DO, Mamdani MM, Kopp A, et al. Proton pump inhibitors and hospitalization for Clostridium difficile–associated disease: a population-based study. Clin Infect Dis. 2006;43:1272–1276
  33. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39:54–59
  34. Gurian L, Ward TT, Katon RM. Possible foodborne transmission in a case of pseudomembraneous colitis due to Clostridium difficile: influence of gastro-intestinal secretions on Clostridium difficile infection. Gastroenterology. 1982;83:465–469
  35. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12:409–415
  36. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363–372
  37. Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J. 2005;173:1037–1042
  38. Kutty P, Benoit S, Woods C, et al. Emerging Clostridium difficile-associated disease in the community and the role of non-antimicrobial risk factors. Abstracts of the 44th Annual Meeting of the Infectious Diseases Society of America (IDSA), October 12-15, 2006, Toronto, Ontario, Canada, P. 242 [Abstract LB-28].
  39. Klein EJ, Boster DR, Stapp JR, et al. Diarrhea etiology in a children’s hospital emergency department: a prospective cohort study. Clin Infect Dis. 2006;43:807–813
  40. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–2441
  41. Samore M, Killgore G, Johnson S, et al. Multicenter typing comparison of sporadic and outbreak Clostridium difficile isolates from geographically diverse hospitals. J Infect Dis. 1997;176:1233–1238
  42. Centers for Disease Control and Prevention. Data and Statistics about Clostridium difficile Infections. Available at: http://www.cdc.gov/ncidod/dhqp/id_Cdiff_data.html. Accessed October 2, 2006.
  43. Valiquette L, Low DE, Pépin J, McGeer A. Clostridium difficile infection in hospitals: a brewing storm. Can Med Assoc J. 2004;171:27–29
  44. Loo VG, Libman MD, Miller MA, et al. Clostridium difficile: a formidable foe. Can Med Assoc J. 2004;171:47–48
  45. Pépin J, Valiquette L, Alary M-E, et al. Clostridium difficile–associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J. 2004;171:466–472
  46. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile–associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273–280
  47. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile–associated enteric disease. Ann Intern Med. 2006;145:758–764
  48. Muto CA. Poor outcomes associated with Clostridium difficile (CD)–associated diarrhea: identification and control. Management of increasingly frequent and severe Clostridium difficile–associated disease. 2006;Satellite Symposium during Digestive Disease Week 2006, Los Angeles, CA, May 21
  49. Wilkins TD, Lyerly DM. Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol. 2003;41:531–534
  50. Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile–associated diarrhea and colitis (SHEA Position Paper). Infect Control Hosp Epidemiol. 1995;16:459–477
  51. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile–associated diarrhea and colitis (Practice Guidelines). Am J Gastroenterol. 1997;92:739–750
  52. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile–associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5:549–557
  53. ASHP. Therapeutic Position Statement on the preferential use of metronidazole for the treatment of Clostridium difficile–associated disease. Am J Health Syst Pharm. 1998;55:1407–1411
  54. Bartlett JG, Perl TM. The new Clostridium difficile—what does it mean?. N Engl J Med. 2005;353:2503–2505
  55. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586–1590
  56. Pépin J, Alary M-E, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591–1597
  57. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913–1918
  58. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works?. J Med Microbiol. 2005;54:101–111
  59. Buggy BP, Fekety R, Silva J. Therapy of relapsing Clostridium difficile–associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol. 1987;9:155–159
  60. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769–1775
  61. Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile–associated diarrhea. Clin Infect Dis. 2006;43:547–552
  62. Surawicz CM, McFarland LV, Greenberg LN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012–1017
  63. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189–193
  64. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile–associated diarrhea. Gastroenterology. 2005;128:764–770
  65. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006;49:640–645
  66. Mulligan ME, George WL, Rolfe RD, et al. Epidemiologic aspects of Clostridium difficile–induced diarrhea and colitis. Am J Clin Nutr. 1980;33:2533–2538
  67. McFarland LV, Stamm WE. Review of Clostridium difficile–associated diseases. Am J Infect Control. 1986;14:99–109
  68. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? (A systematic review). BMC Infect Dis. 2006;6:130
  69. Boyce JM, Ligi C, Kohan C, et al. Lack of association between the increased incidence of Clostridium difficile–associated disease and the increasing use of alcohol-based hand rubs. Infect Control Hosp Epidemiol. 2006;27:479–483
  70. Loeb M, Simor AE, Landry L, et al. Antibiotic use in Ontario facilities that provide chronic care. J Gen Intern Med. 2001;16:376–383
  71. Montgomery P, Semenchuk M, Nicolle LE. Antimicrobial use in nursing homes in Manitoba. J Geriatr Drug Ther. 1995;9:55–74
  72. Lee YL, Thrupp LD, Lee R, et al. Infection surveillance and antibiotic utilization in a community-based skilled nursing facility. Aging Clin Exp Res. 1996;8:113–122
  73. Mylotte JM. Measuring antibiotic use in a long-term care facility. Am J Infect Control. 1996;24:174–179
  74. Jacobson C, Strausbaugh LJ. Incidence and impact of infection in a nursing home care unit. Am J Infect Control. 1990;18:151–159
  75. Katz PR, Beam TR, Brand F, et al. Antibiotic use in the nursing home (Physician practice patterns). Arch Intern Med. 1990;150:1465–1468
  76. Climo MW, Israel DS, Wong ES, et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile–associated diarrhea and cost. Ann Intern Med. 1998;128:989–995
  77. O’Connor KA, Kingston M, O’Donovan M, et al. Antibiotic prescribing policy and Clostridium difficile diarrhoea. Q J Med. 2004;97:423–429
  78. Ludlam H, Brown N, Sule O, et al. An antibiotic policy associated with reduced risk of Clostridium difficile–associated diarrhoea. Age Ageing. 1999;28:578–580

PII: S0197-4572(07)00056-0

doi: 10.1016/j.gerinurse.2007.02.003

Geriatric Nursing
Volume 28, Issue 3 , Pages 171-181 , May 2007

Article Tools

* Image Usage & Resolution